secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2022-05-02T23:59:59+00:00
Accession:  0000950170-22-006866
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics Reports Q1 2022 Net Loss of $35.6M and Provides Clinical Milestones
--------------------------------------------------------------------------------

- Net loss for Q1 2022 was $35.6 million ($0.69 per share) vs. $25.0 million in Q1 2021.
- Cash, cash equivalents and marketable securities totaled $323.2 million as of March 31, 2022.
- R&D expenses were $28.2 million in Q1 2022, up from $18.6 million in Q1 2021.
- Company plans to submit IND response for DYNE-251 in DMD and regulatory filings for DYNE-101 in DM1 in Q2 2022.
- Initiation of multiple ascending dose clinical trials for DYNE-251 and DYNE-101 anticipated in mid-2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022006866/0000950170-22-006866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022006866/dyn-20220502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-006866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer